Mergers & acquisitions advisory

Life sciences deals need diligence on the science and the business

Scientific, regulatory, medical, financial, and strategic evaluation in one integrated review.

Talk to our team See the evidence

Bracken evaluates pharmaceutical and radiopharmaceutical assets for investors, licensors, and acquirers, from first screen through post-close integration.

4 deal types Venture capital, private equity, licensing, and M&A
Screen to close SWOT screening, in-depth diligence, and integration support
Seed to F500 Client scale, from startups to Fortune 500

What We Do

Bracken's life sciences due diligence determines the real value and status of a target: the science, the regulatory path, the clinical evidence, and the business case behind them. We join an existing deal team for one workstream or own the diligence process entirely.

  • Scientific and technical evaluation of pharmaceutical and radiopharmaceutical assets
  • Diligence on clinical services organizations and imaging technology platforms
  • Full regulatory gap analysis and pathway risk review
  • Medical and clinical development program review
  • Intellectual property and business gap analyses
  • Competitive landscape analysis, including drugs in development and their stage
  • Market sizing, commercial due diligence, and market validation
  • Risk assessment and mitigation proposals
  • Business plans for companies seeking investment or strategic partners
  • Post-close merger and integration support

Bracken provides this expertise on an as-needed basis, so deal teams get senior scientific, regulatory, and medical judgment without adding full-time diligence staff, and existing staff stay billable. When a newly acquired program needs an ongoing operating function, it can continue through our Functional Service Provider model. Regulatory diligence draws on the same team as Regulatory Affairs, and radiopharmaceutical targets on our Radiopharmaceutical Strategy & Operations group.

Where Bracken Fits in the Deal

  1. 1

    Screen

    High-level SWOT analysis across multiple opportunities, so you know which ones deserve a closer look.

  2. 2

    Diligence

    In-depth scientific, regulatory, medical, IP, and commercial review of the companies under serious consideration.

  3. 3

    Decide

    Risks quantified and paired with mitigation proposals, so it's the right deal at the right time for your organization.

  4. 4

    Integrate

    Post-close support that reduces risk, accelerates integration, and shortens the ROI timeline.

See the Evidence

Our Consultants

Former C-suite executives, regulatory specialists, physicians, and scientists. Full profiles and credentials.

Meet the Team

Our Publications

Peer-reviewed publications, book chapters, and patents from the consultants who would work on your deal.

Browse Publications

Client Case Studies

Published engagements including radiopharmaceutical due diligence, imaging endpoint rescues, and regulatory readiness.

Case Study Library
FDA Meeting Request Calculator Model the FDA response and meeting timeline a target's program is facing.
Use the Calculator

Questions

What does life sciences due diligence cover at Bracken?
Everything that determines the real value and status of a target: scientific, regulatory, and medical evaluation alongside financial, strategic, and operational business review. That includes regulatory gap analysis, intellectual property and competitive landscape review, market sizing, SWOT analysis, and risk assessment with mitigation proposals.
Who does Bracken perform due diligence for?
Venture capital and private equity firms, licensing and business development teams, and corporate acquirers evaluating a deal. Bracken also works with companies on the other side of the table, preparing for investment or strategic partnering, including business plans that tie the science to the regulatory, financial, and commercial path.
What kinds of assets and companies can Bracken evaluate?
Pharmaceutical and radiopharmaceutical assets, clinical services organizations, and technology platforms that support pharmaceutical, biotechnology, and imaging companies. Bracken undertakes diligence at every stage of product development, from nascent compounds and technologies to commercial-stage products.
Can Bracken work alongside our existing deal advisors?
Yes. Bracken can collaborate with your bankers, lawyers, and other specialists on the scientific, regulatory, and medical workstreams, or own the diligence process entirely. Consultants integrate with your team, processes, and workflow on an as-needed basis, so your own staff stay on billable work.
Does Bracken support integration after the deal closes?
Yes. Post-close merger and integration support is part of the service, aimed at reducing risk, accelerating integration, and improving the ROI timeline. Programs that need an ongoing operating function after close can continue through Bracken's Functional Service Provider model.

Talk to our team

Let's discuss the deal in front of you and what the diligence needs to answer.

Start a conversation